Study of the docking-dependent PLK1 phosphorylation of the CDC25B phosphatase

Biochemical and Biophysical Research Communications

Volumn 410, Issue 1, 2011, Pages 87-90

  Lobjois, Valérie ^a,b   Froment, Carine ^d,e   Braud, Emmanuelle ^f,g   Grimal, Fanny ^f   Burlet Schiltz, Odile ^d,e   Ducommun, Bernard ^a,b,c   Bouche, Jean Pierre ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CNRS   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

^f INSERM   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

CDC25B; Cell cycle; Mass spectrometry; PLK1; Proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATE; OXYGEN; OXYGEN 18; POLO LIKE KINASE 1; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DOCKING; PRIORITY JOURNAL; REGULATORY MECHANISM;

AMINO ACID SEQUENCE; CDC25 PHOSPHATASES; CELL CYCLE PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SERINE;

EID: 79959374015     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.110     Document Type: Article

References (25)

1. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat. Rev. Cancer 2007, 7:495-507.
2. Jullien D., Bugler B., Dozier C., Cazales M., Ducommun B. Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2/M checkpoint recovery. Cancer Res. 2011, 71:1968-1977.
3. Boutros R., Dozier C., Ducommun B. The when and whereas of CDC25 phosphatases. Curr. Opin. Cell Biol. 2006, 18:185-191.
4. Baldin V., Theis-Febvre N., Benne C., Froment C., Cazales M., Burlet-Schiltz O., Ducommun B. PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation. Biol. Cell. 2003, 95:547-554.
5. Bulavin D.V., Higashimoto Y., Demidenko Z.N., Meek S., Graves P., Phillips C., Zhao H., Moody S.A., Appella E., Piwnica-Worms H., et al. Dual phosphorylation controls CDC25 phosphatases and mitotic entry. Nat. Cell Biol. 2003, 5:545-551.
6. Kramer A., Mailand N., Lukas C., Syljuasen R.G., Wilkinson C.J., Nigg E.A., Bartek J., Lukas J. Centrosome-associated CHK1 prevents premature activation of Cyclin-B-CDK1 kinase. Nat. Cell Biol. 2004, 6:884-891.
7. Lemaire M., Froment C., Boutros R., Mondesert O., Nebreda A.R., Monsarrat B., Ducommun B. CDC25B Phosphorylation by p38 and MK-2. Cell Cycle 2006, 5:1649-1653.
8. Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 2005, 17:37-48.
9. Mirey G., Chartrain I., Froment C., Quaranta M., Bouche J.P., Monsarrat B., Tassan J.P., Ducommun B. CDC25B phosphorylated by pEg3 localizes to the centrosome and the spindle poles at mitosis. Cell Cycle 2005, 4:806-811.
10. Schmitt E., Boutros R., Froment C., Monsarrat B., Ducommun B., Dozier C. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J. Cell Sci. 2006, 119:4269-4275.
11. Cazales M., Schmitt E., Montembault E., Dozier C., Prigent C., Ducommun B. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle 2005, 4:1233-1238.
12. Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., Mirey G., Bouche J., Theis-Febvre N., Schmitt E., et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2/M transition. J. Cell Sci. 2004, 117:2523-2531.
13. Theis-Febvre N., Filhol O., Froment C., Cazales M., Cochet C., Monsarrat B., Ducommun B., Baldin V. Protein kinase CK2 regulates CDC25B phosphatase activity. Oncogene 2003, 22:220-232.
14. Bouche J.P., Froment C., Dozier C., Esmenjaud-Mailhat C., Lemaire M., Monsarrat B., Burlet-Schiltz O., Ducommun B. NanoLC-MS/MS analysis provides new Insights into the phosphorylation pattern of CDC25B in vivo: full overlap with sites of phosphorylation by CHK1 and CDK1/cycB Kinases in vitro. J. Proteome Res. 2008, 7:1264-1273.
15. Toyoshima-Morimoto F., Taniguchi E., Nishida E. PLK1 promotes nuclear translocation of human CDC25C during prophase. EMBO Rep. 2002, 3:341-348.
16. Elia A.E., Cantley L.C., Yaffe M.B. Proteomic screen finds pSer/pThr-binding domain localizing PLK1 to mitotic substrates. Science 2003, 299:1228-1231.
17. Lowery D.M., Clauser K.R., Hjerrild M., Lim D., Alexander J., Kishi K., Ong S.E., Gammeltoft S., Carr S.A., Yaffe M.B. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a PLK1 substrate. EMBO J. 2007, 26:2262-2273.
18. Park J.E., Soung N.K., Johmura Y., Kang Y.H., Liao C., Lee K.H., Park C.H., Nicklaus M.C., Lee K.S. Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol. Life Sci. 2010, 67:1957-1970.
19. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (PLK1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 1996, 135:1701-1713.
20. Wehrli W.E., Verheyden D.L., Moffatt J.G. Dismutation reactions of nucleoside polyphosphates. Ii. Specific chemical syntheses of alpha-, beta-, and gamma-P32-nucleoside 5′-triphosphates. J. Am. Chem. Soc. 1965, 87:2265-2277.
21. Moffatt J.G., Khorana H.G. The synthesis and some reactions of nucleoside-5′ phosphoromorpholidates and related compounds. Improved methods for the preparation of nucleoside-5′ polyphosphates. J. Am. Chem. Soc. 1961, 83:649-658.
22. Risley J.M., Van Etten R.L. A convenient synthesis of crystalline potassium phosphate-18O4 (monobasic) of high isotopic purity. J. Labeled Compd. Radiopharm. 1978, 15:533-538.
23. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68:850-858.
24. Chopra P., Sethi G., Dastidar S.G., Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert. Opin. Investig. Drugs 2010, 19:27-43.
25. Brezak M.C., Valette A., Quaranta M., Contour-Galcera M.O., Jullien D., Lavergne O., Frongia C., Bigg D., Kasprzyk P.G., Prevost G.P., et al. IRC-083864 a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int. J. Cancer 2009, 124:1449-1456.